Dermatology Expansion Adquey launch in the United States and the establishment of a dedicated dermatology business unit indicate a focused growth path in skin conditions. This presents opportunities to target dermatology clinics, specialty pharmacies, and payer partnerships for topical therapies addressing mild-to-moderate atopic dermatitis.

FDA Collaboration FDA confirmatory trial agreement and subsequent FDA approval for Adquey signal a credible regulatory trajectory. Leverage this momentum to engage clinical research organizations, contract manufacturers, and regional distribution partners to scale trials, manufacturing, and commercialization.

Strategic Partnerships Collaboration with Otsuka for Adquey underscores openness to co-development and co-commercialization models. Explore co-promotion, licensing, and strategic alliances with mid-to-large pharma players to expand reach and share development costs.

Financial Scale Revenue range of 25–50 million positions Acrotech as a mid-market partner with sizable volume needs. Target suppliers, contract manufacturers, clinical services, and distribution networks that can support scalable production, pharmacovigilance, and nationwide market access.

Global Platform As a global platform focused on innovative proprietary medications, Acrotech seeks to commercialize advanced therapeutics. Identify opportunities in international market entry, regulatory consulting, and patient access programs to accelerate launches and expand patient reach.